Company Overview and News

KLCI pares loss as region remains weaker

2018-10-09 theedgemarkets
KUALA LUMPUR (Oct 9): The FBM KLCI pared some of its losses at the midday break today, against a backdrop of weaker regional markets.
HLFBF UPBMF 7036 1082 5010 BATS 4162 2291 7765 3794 2089 5256 9334 5199 KLKBY 5139 2445 0900 8613 6888 AXXTF 5827 HIPEF 3719

Stronger earnings anticipated for Enra in coming quarters

2018-08-15 theedgemarkets
Enra Group Bhd (Aug 14, RM2.30) Maintain hold with an unchanged fair value (FV) of RM1.85: Enra Group Bhd registered a first quarter ended June 30, 2018 (1QFY19) net profit of RM1.2 million (+17.9% year-on-year [y-o-y] mainly due to a higher contribution from the energy services division.

KLCI reverses earlier losses, select blue chips lift

2018-08-14 theedgemarkets
KUALA LUMPUR (Aug 14): The FBM KLCI reversed its earlier losses and clawed into positive territory at mid-morning today, lifted by select blue chips including Tenaga Nasional Bhd.
APEXF 7090 8621 5681 7248 6033 2593 7079 PNADF 5347 5225 8613 6645 TNABY TNABF Q0F IHHHF PNAGF

KLCI rises 0.12%, tracks regional gains

2018-07-25 theedgemarkets
KUALA LUMPUR (July 25): The FBM KLCI advanced 0.12% at the midday break, tracking regional gains, lifted by select index-linked blue chips.
7052 UPBMF 5681 BATS 4162 2089 5255 9334 5199 4588 5347 1201 3301 8613 TNABY 2836 TNABF HIPEF GEBHF 3719

KLCI remains muted despite uptrend at regional markets

2018-07-25 theedgemarkets
KUALA LUMPUR (July 25): The FBM KLCI clawed into positive territory at mid-morning but remained somewhat muted against the backdrop of the positive regional markets.
HLFBF 7052 UPBMF 4065 1082 9679 5245 2089 5255 5436 1201 3301 8613 2739 2836

KLCI pares gains, remains up 0.44% as banks lift

2018-07-19 theedgemarkets
KUALA LUMPUR (July 19): The FBM KLCI pared some its gains at the midday break today and was up 0.44%, against the backdrop of higher regional markets.
PBLOF MLYBY MLYNF 7113 TPGVF 1295 3794 5014 9334 0131 TGLVY 1155 4588 3867 8613 6459 5819 MYPRY 1929

KLCI reverses loss, rises 0.31% in line with region

2018-07-18 theedgemarkets
KUALA LUMPUR (July 18): The FBM KLCI reversed its earlier losses and rose 0.31% at midday break, tracking gains at most Asian markets.
HLFBF 7172 PBLOF 7053 1082 7087 1295 9334 7123 0143 4863 0156 8613 0026 6888 5819 AXXTF MYTEF 2836

KLCI falls 0.77% as Trump's tariffs on China take effect

2018-07-06 theedgemarkets
KUALA LUMPUR (July 6): The FBM KLCI fell 0.77% at midday break as regional markets slumped, as U.S. tariffs against China took effect this afternoon.
PBLOF UPBMF 4065 6399 5681 1295 2089 7055 7154 5255 7277 CIMDF KLKBY 5139 1023 2445 0900 8613 0026 6888 2216 AXXTF

KLCI falls 0.47% in subdued start to 2H2018

2018-07-02 theedgemarkets
KUALA LUMPUR (July 2): The FBM KLCI fell 0.47% at midday break today, as latest data showed business conditions across Malaysia’s manufacturing sector deteriorating, albeit at a slower pace in June.
HLFBF PBLOF 7113 7036 TPGVF 1295 7077 9334 DKSHY 5347 3301 8613 TNABY 5908 HRGHY SPMXF 1082 5681 5168 1481 TGLVY 5139 4588 SPMXY 0900 5819 TNABF DKSHF

KLCI likely to remain muted ahead of Hari Raya break

2018-06-13 theedgemarkets
KUALA LUMPUR (June 14): The FBM KLCI is likely to remain muted today ahead of the Hari Raya Aidilfitri holiday as Bursa Malaysia officially closes after the morning session.
SPMXY 5209 SPMXF 8613 BSMAF MGFCF 1818 5133

Supermax, E.A Technique, Enra, Petra Energy, GFM Services, Mega First and Gas Malaysia

2018-06-13 theedgemarkets
KUALA LUMPUR (June 13): Based on corporate announcements and news flow today, companies in focus on Thursday (June 14) may include: Supermax Corp Bhd, E.A. Technique (M) Bhd, Enra Group Bhd, Petra Energy Bhd, GFM Services Bhd, Mega First Corp Bhd and Gas Malaysia Bhd.
SPMXY 5209 SPMXF 8613 MGFCF 5133

Enra buys Australian specialty chemicals distributor for RM13.5m

2018-06-13 theedgemarkets
KUALA LUMPUR (June 13): Enra Group Bhd is acquiring International Chemicals Engineering Pty Ltd (ICE), an Australian company involved in importing and distributing specialty chemicals in Australia and New Zealand.
8613 BSMAF 1818

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...